A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

Angiogenesis

Volumn 12, Issue 3, 2009, Pages 287-296

  Lamontagne, Kenneth R ^a,b   Butler, Jeannene ^a   Borowski, Virna B ^a   Fuentes Pesquera, Angel R ^a   Blevitt, Jonathan M ^a   Huang, Shenlin ^a   Li, Ronghua ^a   Connolly, Peter J ^a   Greenberger, Lee M ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anti angiogenesis; Tryosine kinase inhibitor; Vascular endothelial growth factor receptor 2

Indexed keywords

1 {4 [6 AMINO 5 (METHOXYIMINO METHYL) PYRIMIDIN 4 YLOXY] 2 CHLORO PHENYL} 3 ETHYL UREA; JNJ 38158471; PROTEIN RET; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COLON POLYPOSIS; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS; OXIMES; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SUBSTRATE SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 70349492706     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-009-9151-7     Document Type: Article

References (35)

1. J Folkman 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 27 31
2. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249-257
3. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669-676
4. DR Senger CA Perruzzi J Feder HF Dvorak 1986 A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines Cancer Res 46 5629-5632
5. N Ferrara WJ Henzel 1989 Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem Biophys Res Commun 161 851-858
6. J Folkman Y Shing 1992 Angiogenesis J Biol Chem 267 10931 10934
7. N Ferrara 1999 Molecular and biological properties of vascular endothelial growth factor J Mol Med 77 527-543
8. B Millauer S Wizigmann-Voos H Schnurch, et al. 1993 High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 72 835-846
9. B Liu HM Earl D Baban, et al. 1995 Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF Biochem Biophys Res Commun 217 721-727
10. J Folkman 1972 Anti-angiogenesis: new concept for therapy of solid tumors Ann Surg 175 409-416
11. Y Takahashi Y Kitadai CD Bucana KR Cleary LM Ellis 1995 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 3964-3968
12. J Drevs I Hofmann H Hugenschmidt, et al. 2000 Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res 60 4819-4824
13. S Emanuel RH Gruninger A Fuentes-Pesquera, et al. 2004 A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models Mol Pharmacol 66 635-647
14. TA Fong LK Shawver L Sun, et al. 1999 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res 59 99 106
15. SR Wedge DJ Ogilvie M Dukes, et al. 2000 ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy Cancer Res 60 970-975
16. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099-7109
17. DM Goldstein NS Gray PP Zarrinkar 2008 High-throughput kinase profiling as a platform for drug discovery Nat Rev Drug Discov 7 391-397
18. K LaMontagne A Littlewood-Evans C Schnell, et al. 2006 Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization Cancer Res 66 221-231
19. BM Kenyon EE Voest CC Chen, et al. 1996 A model of angiogenesis in the mouse cornea Invest Ophthalmol Vis Sci 37 1625-1632
20. AJ Schueneman E Himmelfarb L Geng, et al. 2003 SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res 63 4009-4016
21. K Yang W Edelmann K Fan, et al. 1997 A mouse model of human familial adenomatous polyposis J Exp Zool 277 245-254
22. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab (Bevacizumab) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 713-718
23. MN Stein KT Flaherty 2007 CCR drug updates: sorafenib and sunitinib in renal cell carcinoma Clin Cancer Res 13 3765-3770
24. H Gille J Kowalski B Li, et al. 2001 Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants J Biol Chem 276 3222-3230
25. M Meyer M Clauss A Lepple-Wienhues, et al. 1999 A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases EMBO J 18 363-374
26. H Zeng S Sanyal D Mukhopadhyay 2001 Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively J Biol Chem 276 32714 32719
27. S Rousseau F Houle H Kotanides, et al. 2000 Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase J Biol Chem 275 10661 10672
28. R Roskoski Jr 2008 VEGF receptor protein-tyrosine kinases: structure and regulation Biochem Biophys Res Commun 375 287-291
29. K Holmes OL Roberts AM Thomas MJ Cross 2007 Vascular endothial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition Cell Signal 19 2003-2012
30. J Zhang PL Yang NS Gray 2009 Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 28 39
31. A Viloria-Petit T Crombet S Jothy, et al. 2001 Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 5090-5101
32. F Okada JW Rak BS Croix, et al. 1998 Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells Proc Natl Acad Sci USA 95 3609-3614
33. HP Gerber A McMurtrey J Kowalski, et al. 1998 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation J Biol Chem 273 30336 30343
34. T Kitamura M Itoh T Noda M Matsuura K Wakabayashi 2004 Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice Int J Cancer 109 576-580
35. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342